KaloBios Pharma (NASDAQ: KBIO) ripping higher as Martin Shkreli purchased shares.
Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.
On November 13, 2015, KaloBios announced that it will wind down its operations and that it has engaged the Brenner Group to lead those efforts. As of June 30, 2015, KaloBios had cash, cash equivalents and investments totaling $23.2 million, but announced with the winddown it repaid in full its outstanding secured loan obligation to MidCap Financial, secured lender to the company, in the approximate amount of $6.6 million.
KBIO shares are up over 100 percent after hours. The filing is embedded below:
11/17/2015 Morgan Stanley Lower Price Target from $200.00 to $98.
This junk stock will trade under $50
And this coming from a fool who brought in the mid fifties. LOL... Yell baby your quit the investor!
Definitely going to ZERO. Feel sorry for you bag holders! Stock slides for 6 months in a roll, there something seriously wrong with this company. Hedge funds can't sell there shares fast enough.
Analyst at Jefferies
Wall Street Analyst
Ranked #2,918 out of 3,871 analysts (#6,154 of 8,561 overall experts)
Can we say he sucks as a Analyst? 1 star rating, yes we can say he sucks....
AMAG made another new 52 week low of $28.20. Well the shorts break it down to $27 or will the longs show some balls & force a short squeeze? Time will tell!